CADTH

Provincial Advisory Group Input Template for CADTH pan-Canadian Oncology Drug Review Program

1. Province

- ☐ British Columbia
- ☐ Alberta
- ☐ Saskatchewan
- ☐ Manitoba
- ☐ Ontario
- ☐ Quebec
- ☐ New Brunswick
- ☐ Nova Scotia
- ☐ Newfoundland and Labrador
- ☐ Prince Edward Island
- ☐ Federal Public Drug Benefits Plan

2. About the Drug and Indication Under Review

Generic Drug Name (Brand Name)	
Indication	
Funding Request	
URL to NCT Trial Description (if available)	
URL to Trial Publication (if available)	

3. Key Questions for Provincial Advisory Group Input

3.1. What currently is the standard of care in your province?

3.2. What patient population is not addressed by the trial and should be considered by the review team and the pCODR Expert Review Committee (i.e., generalizability and/or extrapolation of trial data to patients in clinical practice)?

3.3. What group of patients, if any, may have a time-limited need that should be addressed by the review team and pERC?

3.4. What is the potential for indication creep? What would be considered out of scope of the reimbursement request?

3.5. What sequencing issue, treatment and funding algorithm, or place in therapy needs to be addressed by the review team and pERC for implementation?

3.6. Identify implementation issues related to dose, schedule or frequency, drug administration, dose intensity, and dose modifications (e.g., nursing resources, chair time, pre-medications, monitoring resources, frequency of clinic visits) that can be addressed by the review team.

3.7. Identify implementation issues related to dose preparation and dispensing (e.g., pharmacy resources, degree of drug wastage and vial sharing, mandatory controlled distribution program) that can be addressed by the review team.

3.8. Identify additional resources (i.e., those not required with existing treatments) required to monitor, manage, and treat adverse events (e.g., frequency of clinic visits, blood work, supportive drugs such as granulocyte colony-stimulating factor — or G-CSF), ophthalmologist consults, etc.).

3.9. What are the implementation issues related to companion diagnostic tests (e.g., already in the health system, not currently available, turnaround time, number of patients to be tested, timing of testing, reliability of test results, need for test)?

3.10. What key implementation questions can we seek from registered clinicians providing input to support the review and recommendation?